CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 67 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01073462
NCT01073462N/ACompleted
CompareCT.gov

Postmarketing Observational Study to Evaluate the Effect of Zemplar (Paricalcitol IV) on Cardiac Morbidity in Patients With Chronic Kidney Disease Stage 5 Over 2 Years.

AbbVie (prior sponsor, Abbott)·observational·Posted Feb 23, 2010·Updated Jul 10, 2014

In Brief

An observational study for Secondary Hyperparathyroidism and 2 related conditions. Completed, enrolled 67 participants across 12 sites.

Detailed Summary

The purpose of this study was to ascertain the percentage of cardiac patients with chronic kidney disease (CKD) stage 5 treated with paricalcitol IV achieving intact parathyroid hormone (iPTH) levels in target range of Kidney Disease Outcomes Quality Initiative (K/DOQI) treatment guidelines (150 - 300 pg/mL) after 2 years.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSecondary Hyperparathyroidism, Chronic Kidney Disease Stage V, Cardiac Morbidity
CountriesAustria
CollaboratorsAssign Data Management and Biostatistics GmbH

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 23, 2010
Enrollment StartDec 1, 2008
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 16.4 years ago